Akums Drugs and Pharmaceuticals Limited — PPTs, 13-11-2025: Investor Presentation

**1. Business Performance:**

The financial results for the quarter and half-year show H1FY26 revenue largely flat, but margins dipped due to an 8-10% YoY fall in API prices. CDMO volumes grew 7%. Q2FY26 revenue was ₹1,018 Cr (-1.5% YoY) with Adjusted PAT at ₹43 Cr (-35.9% YoY) and Adjusted EBITDA margin of 9.3%.

**2. Growth Drivers or Strategy:**

Focus is on improving margins through superior product mix and cost optimization. Strategies involve scaling domestic & export branded businesses, while reducing API and Trade Generics.

**3. Recent Developments:**

Significant international expansion includes a new JV with the Zambian government to establish a pharmaceutical manufacturing plant (approx. USD 45 million project), also securing USD 50 million in medicine supply over two years. The first commercial formulation supply to Europe (Switzerland) was achieved.

**4. Key Financial Metrics & Outlook:**

H1FY26 saw revenue of ₹2,042 Cr (-0.5% YoY) and Adjusted PAT of ₹107 Cr (-13.4% YoY), with H1 Adjusted EBITDA margin at 10.9%. Management expects a strong H2 for exports and new facilities to contribute in 2026. Over ₹1,600 Cr in net cash provides strong leverage for growth, reinforcing CDMO leadership and expanding branded segments.